Total

pCR (−)

(n = 200)

pCR (+)

(n = 38)

p-value

Age

≤35

62

53 (26.5%)

9 (23.7%)

0.253

35< age ≤45

92

79 (39.5%)

13 (34.2%)

45< age ≤55

57

48 (24.0%)

9 (23.7%)

55< age

27

20 (10.0%)

7 (18.4%)

Mean age (range)

41.9 (25 - 66)

45.3 (31-68)

0.038

Menopause

Post

46

34 (17.0%)

12 (31.6%)

0.045

Pre

192

166 (83.0%)

26 (68.4%)

Family History

None

214

178 (89.0%)

36 (94.7%)

0.386

Breast cancer FHx

24

22 (11.0%)

2 (5.3%)

Regimen

AC/AC + Taxane

144

128 (64%)

16 (42.1%)

0.076

AC + Taxane + Herceptin

57

43 (21.5%)

14 (36.8%)

AC + Paclitaxel + Carboplatin

13

12 (6.0%)

1 (2.6%)

TCHP

8

3 (1.5%)

5 (13.2%)

Others

16

14 (7.0%)

2 (5.3%)

Pathology

IDC

229

191 (95.5%)

38 (100%)

0.334

ILC

3

3 (1.5%)

0

Mixed

6

6 (3.0%)

0

Subtype

HR+/HER2−*

57

54 (27.0%)

3 (7.9%)

0.570

HR+/HER2+^#

31

20 (10.0%)

11 (28.9%)

HR−/HER2+

39

31 (15.5%)

8 (21.1%)

HR−/HER2−

111

95 (47.5%)

16 (42.1%)

Multiplicity

None

121

98 (49.0%)

23 (60.5%)

0.218

Multiplicity

117

102 (51.0%)

15 (39.5%)

T stage

1

41

31 (15.5%)

10 (26.3%)

0.107

2

108

92 (46.0%)

16 (42.1%)

3

87

76 (38.0%)

11 (28.9%)

4

2

1 (0.5%)

1 (2.6%)

Axillary Nodal evaluation

Clinical N0

35

30 (15.0%)

5 (13.2%)

0.431

Axillary FNA negative

48

42 (21.0%)

6 (15.8%)

Axillary FNA positive

155

128 (64.0%)

27 (71.1%)

SCN FNA

Undone

225

169 (94.5%)

36 (94.7%)

1.000

Positive

13

11 (5.5%)

2 (5.3%)

Negative

0

0 (0.0%)

0 (0.0%)

IMLN FNA

Undone

226

189 (94.5%)

37 (97.4%)

1.000

Positive

11

11 (5.5%)

0 (0.0%)

Negative

1

0 (0.0%)

1 (2.6%)

Ki-67

1

37

34 (17.0%)

3 (7.9%)

1.000

2

72

54 (27.0%)

18 (47.4%)

3

48

44 (22.0%)

4 (10.5%)

4

81

68 (34.0%)

13 (34.2%)

Tumor marker

CEA elevation

10

8 (4.0%)

2 (5.3%)

1.000

None

228

192 (96.0%)

36 (94.7%)

CA15-3 elevation

19

18 (9.0%)

1 (2.6%)

0.219

None

219

182 (91.0%)

37 (97.4%)

Gene profile

ESR mutation

10

10 (5.0%)

0 (0.0%)

0.226

Wild type

228

190 (95.0%)

38 (100.0%)

EGFR mutation

17

16 (8.0%)

1 (2.6%)

0.323

Wild type

221

184 (92.0%)

37 (97.4%)

ERRB2 mutation

72

57 (28.5%)

15 (39.5%)

0.183

Wild type

166

143 (71.5%)

23 (60.5%)

PIK3CA mutation

50

43 (21.5%)

7 (18.4%)

0.829

Wild type

188

157 (78.5%)

31 (81.6%)

BRCA1 mutation

70

58 (29.0%)

12 (31.6%)

0.846

Wild type

168

142 (71.0%)

26 (68.4%)

BRCA2 mutation

79

73 (36.5%)

6 (15.8%)

0.014

Wild type

159

127 (63.5%)

32 (84.2%)

TP53 mutation

189

161 (80.5%)

28 (73.7%)

0.382

Wild type

49

39 (19.5%)

10 (26.3%)

PTEN mutation

25

24 (12.0%)

1 (2.6%)

0.143

Wild type

213

176 (88.0%)

37 (97.4%)